OCAST Deadlines – see the OTHER DEADLINES Section below.
List of Oklahoma Center for Adult Stem Cell Research (OCASCR) Equipment available to all scientists in Oklahoma is at:
Would you like assistance with your research, case study or QI project from an OU College of Medicine student? Medical students are eager to gain research experience and to help OU faculty and residents with their projects. Students are interested in paid or unpaid positions and available time varies by their year in the curriculum. Simply share some basic information regarding your project on the Student Research Opportunities Portal in order to have an interested student contact you. (https://com.ouhsc.edu/research-project?posting)
PLEASE NOTE: Change to OUHSC new NIH Other Support pages requirements. OUHSC will not start implementing this policy internally until October 01, 2021 (previously July 1, 2021). Please keep in mind, that other institutions may have already implemented this policy and you may be required to use the new format for them before the OUHSC October 01, 2021 date.
Effective immediately, all Human Subject Research (HSR) activities including clinical trials are allowed to resume provided all OUHSC COVID-19 safety protocols can be met. It is expected that all personnel will adhere to the requirements in the OUHSC COVID-19 Response Plan. If your current HSR protocol was temporarily halted due to the COVID-19 restrictions, the HRPP Office will update the study status of those protocols without any action required from you.
Also, in accordance with campus policy, our research laboratories* remain closed to K-12 students for shadowing, volunteer, and educational purposes, but open to visitors, undergraduates, graduates, and post-docs from any institution for those purposes, provided the following are observed by these individuals. The manager of the area where these individuals will be is responsible for compliance:
- non-HSC individuals will complete the online visitor screening tool prior to their first day on campus individuals will be required to show proof of a negative COVID test (within past 48 hours) or documentation of COVID vaccination, if required based on screening results
- all individuals will complete the HSC online COVID-19 training module in OnPoint, using their HSC credentials
- all individuals (including students, faculty, staff, and volunteers) will comply with OU’s COVID-19 vaccine policy:
- those with patient-facing or research participant-facing responsibilities or who will be in patient care or human research
- all other individuals will be strongly encouraged to be vaccinated against COVID-19
* all individuals will be informed that they must comply with and be given the link to the HSC COVID-19 Response Plan
*Rotations in clinical areas on campus and at OUMI are limited to OUHSC students, at least through July 2021. With these changes, we are retiring the Return to Research Plan and will refer to the OUHSC COVID Response Plan for COVID protocols. If you identify a deficiency caused by this action, please email email@example.com.
OK-INBRE REQUEST FOR APPLICATIONS FOR RESEARCH PROJECTS
The Oklahoma IDeA Network of Biomedical Research Excellence (OK-INBRE) is requesting applications for research projects from full-time, tenure track faculty (or equivalent) at the University of Oklahoma Health Sciences Center (OUHSC) or the Oklahoma Medical Research Foundation (OMRF). OK-INBRE will fund four Research Project Investigator (RPI) Awards with a start date of November 1, 2021 and an end date of April 30, 2024. Funding for awards is anticipated to be $100,000 in direct costs per year. Applications must align with one of the OK-INBRE research themes of 1) Cancer, 2) Developmental Biology, or 3) Infectious Diseases. The application deadline is 5pm on August 13, 2021. Please see the attached funding opportunity announcement for details. Information can also be found on the OK-INBRE website at Funding Opportunities for OUHSC and OMRF. Questions regarding this OK-INBRE opportunity can be sent to Dawn Hammon (firstname.lastname@example.org) or Darrin Akins (email@example.com).
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email firstname.lastname@example.org or email@example.com).
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/ cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies. Proposal template available upon request (submission deadline 6/18/21).
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
AHRQ Policy on the Inclusion of Priority Populations in Research (NOT-HS-21-015)
Announcing New Inbox for Inquiries Related to Changes to Biographical Sketch and Other Support Format Page (NOT-OD-21-122)
Notice of Information: NIDA Extensions for NRSA Fellowships and Career Development Award Recipients Whose Career Trajectories Have Been Significantly Affected by COVID-19 (NOT-DA-21-046)
Notice of Pre-Application Information Webinar for PAR-21-183, "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" (NOT-DA-21-052)
NIDDK Notice of Continuation of Temporary Extension of Eligibility for the NIH Mentored Research Scientist Development Award (K01) Award During the COVID-19 Pandemic (NOT-DK-21-019)
Notice of a Pre-Application Technical Assistance Webinar for NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00) (NOT-NS-21-067)
Notice to Extend the Response Date for NOT-OD-21-108 "Request for information (RFI) on enhancing the science for the Environmental influences on Child Health Outcomes (ECHO) program" (NOT-OD-21-129)
Request for Information (RFI): Inviting Comments and Suggestions on the Impact of Radiation Exposure from a Radiological or Nuclear Incident on the Microbiome and the Development of Targeted Therapeutics (NOT-AI-21-055)
Request for Information (RFI): Inviting Comments on Developing Evidence-Based Music Therapies for Brain Disorders of Aging (NOT-AT-21-011)
Request for Information (RFI): Access and Use of Data from the Adolescent Brain Cognitive Development (ABCD) Study (NOT-DA-21-055)
Request for Information: Input to the National Eye Institute Strategic Plan Draft Document
Notice of Change to Award Information in PAR-21-082, "NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) (NOT-AI-21-053)
Notice of Change of Second Available Due Date for NOT-HD-20-008, Notice of Special Interest: Ancillary Reproductive Health Projects to Existing Large and/or Longitudinal Studies (NOT-HD-21-034)
Notice of Participation of NIMH in PAR-20-125, "Native American Research Centers for Health (NARCH) (S06 Clinical Trials Optional)" (NOT-MH-21-300)
Notice of Early Termination of RFA-NS-21-016, HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed) (NOT-NS-21-061)
Notice to Extend the Expiration Date for PA-18-590 Change of Grantee Organization (Type 7 Parent Clinical Trial Optional) (NOT-OD-21-121)
Correction to the Budget Section of PAR-21-225"Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)" (NOT-OD-21-123)
Correction to the Budget Section of "PAR-21-226 Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)" (NOT-OD-21-124)
Correction to the Eligibility Section of PAR-21-238 "Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (NOT-OD-21-126)
Notice of Participation of the Office of Research on Women's Health (ORWH) in PAR-20-214, "Research to Improve Native American Health (R21 Clinical Trials Optional)" (NOT-OD-21-132)
Notice of Participation of the Office of Research on Women's Health (ORWH) in PAR-20-238, "Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)" (NOT-OD-21-133)
Notice of Addition of Information for RFA-RM-21-021 - Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) (NOT-RM-21-027)
Notice of Addition of Information for RFA-RM-21-022 - Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Allowed) (NOT-RM-21-028)
Notice of Special Interest: Advanced Computational Approaches to Elucidate Disease Pathology and Identify Novel Therapeutics for Addiction (NOT-DA-21-004)
Notice of Special Interest: Administrative Supplements to Support Research on Health Equity in NIDA-funded Grant Awards (NOT-DA-21-044)
Notice of Special Interest (NOSI): Administrative Supplements to Support Engagement of Functionally Diverse Teams to Advance Ongoing NIDA-funded Research (NOT-DA-21-045)
Notice of Special Interest (NOSI) to Encourage Administrative Supplement Applications to Investigate COVID-19 Vaccination and Menstruation (Admin Supp Clinical Trial Optional) (NOT-HD-21-035)
Notice of Special Interest (NOSI): Re-issue of Availability of Administrative Supplements for Submission of Tissue Chip Data to the Microphysiology Systems Database (MPS-Db) (NOT-TR-21-028)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required) (PAR-21-154) Deadline June 25, 2021 and October 25, 2021
Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) (PAR-21-155) Deadline June 25, 2021 and October 25, 2021
NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) (PAR-21-237) - Deadline June 25, 2021 and October 13, 2021
Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) (RFA-DK-21-012) – Deadline March 9, 2022 and October 7, 2022
NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional) (RFA-RM-21-016) Deadline August 20, 2021
Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional) (RFA-TW-21-004) - Deadline August 20, 2021
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Scleroderma Research Program (SRP) - Idea Development Award – Required PreApplication due August 11, 2021
DOD – SRP – Translational Research Partnership Award - Required PreApplication due August 11, 2021
DOD – Alzheimer’s Research Program (PRARP) – Convergence Science Program – Required PreApplication due June 14, 2021
DOD – PRARP – Innovation in Care and Support Award – Required PreApplication due June 14, 2021
DOD – PRARP – Research Partnership Award – Required PreApplication due June 14, 2021
DOD – PRARP – Accelerating Diagnostic Research Award – Required PreApplication due June 14, 2021
DOD – PRARP – Leveraging Approaches for Innovation in Care and Support Award – Required PreApplication due June 14, 2021
Alex’s Lemonade Stand – ALSF Young Investigator Grant – Deadline July 12, 2021
Cure Epilepsy – Catalyst Award – Letter of Intent Due June 30, 2021 and Proposal Deadline Septem,ber 10, 2021
Damon Runyon Cancer Research Foundation – Innovation Award – Deadline July 1, 2021
Diabetes Research and Wellness Foundation – Research Grants – Deadline June 30, 2021 and December 30, 2021
Oklahoma Center for the Advancement of Science and Technology (OCAST) – Health Research Program Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Health Research Postdoctoral Fellowship - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Oklahoma Applied Research Support (OARS) Program - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
OCAST – Intern Partnership Program - Deadline July 2, 2021 NO LATER THAN 5:00 PM Central Time
Chan Zuckerberg Initiative – Expanding Global Access to Bioimaging – Deadline July 20, 2021